Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.

Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Zhu JJ, Wang SY, Qiu DK.

J Dig Dis. 2013 Aug;14(8):439-45. doi: 10.1111/1751-2980.12066.

PMID:
23638710
2.

Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors.

Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, Jawan B, Chiu KW, Chen CL.

Clin Transplant. 2002 Dec;16(6):405-9.

PMID:
12437618
3.

High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.

Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, Chang MH, Lee PH.

J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):203-8. doi: 10.1097/MPG.0b013e3181819ad4.

PMID:
19179883
4.

Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients.

Lin CC, Chen CL, Concejero A, Wang CC, Wang SH, Liu YW, Yang CH, Yong CC, Lin TS, Jawan B, Cheng YF, Eng HL.

Am J Transplant. 2007 Jan;7(1):195-200.

5.

De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.

Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, García-Herola A, Nicolás D, Carrasco D, Orbis JF, Mir J, Berenguer J.

Liver Transpl. 2001 Jan;7(1):51-8.

6.

Liver grafts from anti-hepatitis B core positive donors: a systematic review.

Cholongitas E, Papatheodoridis GV, Burroughs AK.

J Hepatol. 2010 Feb;52(2):272-9. doi: 10.1016/j.jhep.2009.11.009. Epub 2010 Jan 19. Review.

7.

Transplantation of livers from hbc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results.

Loss GE, Mason AL, Blazek J, Dick D, Lipscomb J, Guo L, Perrillo RP, Eason JD.

Clin Transplant. 2001;15 Suppl 6:55-8.

PMID:
11903388
8.

Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.

Castells L, Vargas V, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF, Jardí R, Margarit C, Pumarola T, Esteban R, Guardia J.

Liver Transpl. 2002 Oct;8(10):892-900.

9.

De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.

Ueda Y, Marusawa H, Egawa H, Okamoto S, Ogura Y, Oike F, Nishijima N, Takada Y, Uemoto S, Chiba T.

Antivir Ther. 2011;16(4):479-87. doi: 10.3851/IMP1771.

PMID:
21685535
10.

Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation.

Rao W, Xie M, Yang T, Zhang JJ, Gao W, Deng YL, Zheng H, Pan C, Liu YH, Shen ZY.

World J Gastroenterol. 2014 Sep 28;20(36):13159-66. doi: 10.3748/wjg.v20.i36.13159.

11.

De novo and apparent de novo hepatitis B virus infection after liver transplantation.

Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, David MF, Arulnaden JL, Bismuth A, Reynes M, Bismuth H.

J Hepatol. 1997 Mar;26(3):517-26.

PMID:
9075658
12.

Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.

Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL.

Liver Transpl. 2001 Jun;7(6):513-7.

13.

Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors.

Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ.

Transplantation. 1999 Oct 15;68(7):1058-61.

PMID:
10532552
14.

Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.

Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, Samuel D.

Liver Transpl. 2010 Jul;16(7):885-94. doi: 10.1002/lt.22084.

15.

Living donor liver transplantation from hepatitis B core antibody positive donors.

Celebi Kobak A, Karasu Z, Kilic M, Ozacar T, Tekin F, Gunsar F, Ersoz G, Yuzer Y, Tokat Y.

Transplant Proc. 2007 Jun;39(5):1488-90.

PMID:
17580169
16.

Low prevalence of HBV DNA in the liver allograft from anti-HBc-positive donors: a single-center experience.

Pan JJ, Oh SH, Soldevila-Pico C, Nelson DR, Liu C.

Clin Transplant. 2011 Jan-Feb;25(1):164-70. doi: 10.1111/j.1399-0012.2010.01211.x.

17.

Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.

Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, Guarrera JV, Emond JC, Brown RS Jr.

Transplantation. 2013 Apr 15;95(7):960-5. doi: 10.1097/TP.0b013e3182845f97.

PMID:
23545507
18.

Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor.

Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC.

Am J Transplant. 2006 May;6(5 Pt 1):1077-83.

19.

Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.

Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H.

Liver Int. 2005 Dec;25(6):1169-74.

PMID:
16343068
20.

Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area.

Ko WJ, Chou NK, Hsu RB, Chen YS, Wang SS, Chu SH, Lai MY.

J Heart Lung Transplant. 2001 Aug;20(8):865-75.

PMID:
11502409

Supplemental Content

Support Center